LakeShore Biopharma Co., Ltd.
DelistedCIK 1946399fmd_0HMSTJQ8TZADDJZNRPA94T5NJGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2020 to Mar 31, 2025, 5 periods
Latest annual · FY2025
Millions- Total revenues
- 615
- Gross profit
- 507
- Operating income
- (86)
- Net income
- (100)
- Free cash flow
- (134)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +6.9%
LakeShore Biopharma Co., Ltd. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | CN¥615 million | CN¥573.4 million | +7.2% | 20-F 2025-07-31 · proof |
| Gross profit | CN¥507.2 million | CN¥455.7 million | +11.3% | 20-F 2025-07-31 · proof |
| Operating income | -CN¥86.3 million | -CN¥445.8 million | 20-F 2025-07-31 · proof | |
| Net income | -CN¥100 million | -CN¥433.5 million | 20-F 2025-07-31 · proof | |
| Cash from operating activities | -CN¥121 million | -CN¥295.2 million | 20-F 2025-07-31 · proof | |
| Free cash flow | -CN¥133.7 million | -CN¥339.5 million | 20-F 2025-07-31 · proof | |
| Total assets | CN¥1.4 billion | CN¥1.5 billion | -9.6% | 20-F 2025-07-31 · proof |
| Total liabilities | CN¥867.9 million | CN¥927.8 million | -6.5% | 20-F 2025-07-31 · proof |
| Cash and cash equivalents | CN¥107.5 million | CN¥246.6 million | -56.4% | 20-F 2025-07-31 · proof |
| Total debt | CN¥413.9 million | CN¥417.5 million | -0.9% | 20-F 2025-07-31 · proof |
- What was LakeShore Biopharma Co., Ltd.'s revenue in fiscal 2025?
- LakeShore Biopharma Co., Ltd. reported revenue of CN¥615 million for fiscal 2025 (the year ended Mar 31, 2025), against CN¥573.4 million the year before (+7.2%). Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What was LakeShore Biopharma Co., Ltd.'s gross profit in fiscal 2025?
- LakeShore Biopharma Co., Ltd. reported gross profit of CN¥507.2 million for fiscal 2025 (the year ended Mar 31, 2025), against CN¥455.7 million the year before (+11.3%). Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What was LakeShore Biopharma Co., Ltd.'s operating income in fiscal 2025?
- LakeShore Biopharma Co., Ltd. reported operating income of -CN¥86.3 million for fiscal 2025 (the year ended Mar 31, 2025), against -CN¥445.8 million the year before. Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What was LakeShore Biopharma Co., Ltd.'s net income in fiscal 2025?
- LakeShore Biopharma Co., Ltd. reported net income of -CN¥100 million for fiscal 2025 (the year ended Mar 31, 2025), against -CN¥433.5 million the year before. Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What was LakeShore Biopharma Co., Ltd.'s cash from operating activities in fiscal 2025?
- LakeShore Biopharma Co., Ltd. reported cash from operating activities of -CN¥121 million for fiscal 2025 (the year ended Mar 31, 2025), against -CN¥295.2 million the year before. Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What was LakeShore Biopharma Co., Ltd.'s free cash flow in fiscal 2025?
- LakeShore Biopharma Co., Ltd. reported free cash flow of -CN¥133.7 million for fiscal 2025 (the year ended Mar 31, 2025), against -CN¥339.5 million the year before. Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What are LakeShore Biopharma Co., Ltd.'s total assets?
- As of Mar 31, 2025, LakeShore Biopharma Co., Ltd. reported total assets of CN¥1.4 billion, against CN¥1.5 billion a year earlier (-9.6%). Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What are LakeShore Biopharma Co., Ltd.'s total liabilities?
- As of Mar 31, 2025, LakeShore Biopharma Co., Ltd. reported total liabilities of CN¥867.9 million, against CN¥927.8 million a year earlier (-6.5%). Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What are LakeShore Biopharma Co., Ltd.'s cash and cash equivalents?
- As of Mar 31, 2025, LakeShore Biopharma Co., Ltd. reported cash and cash equivalents of CN¥107.5 million, against CN¥246.6 million a year earlier (-56.4%). Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
- What is LakeShore Biopharma Co., Ltd.'s total debt?
- As of Mar 31, 2025, LakeShore Biopharma Co., Ltd. reported total debt of CN¥413.9 million, against CN¥417.5 million a year earlier (-0.9%). Source: the 20-F filed with the SEC on Jul 31, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1946399&period_type=annual&limit=5"Information only, not investment advice.